CURE Alzheimer's Fund (October 18, 2012): $5.4 Million Awarded for Research to Guide Alzheimer's Drug Development

Publication Date: 
Thu, 10/18/2012

Understanding who is most susceptible to Alzheimer's disease and developing early detection models, effective therapies and possibly a cure, is the goal of the largest single private scientific grant ever invested in Alzheimer's Whole Genome Sequencing (WGS) focused on families afficted with Alzheimer's disease.

A $5.4 million contribution announced today from the non-profit Cure Alzheimer's Fund to Massachusetts General Hospital (MGH) will allow state-of-the-art whole genome DNA sequencing to further understand the genetic roots of Alzheimer's disease.

Over the last eight years, the Cure Alzheimer's Fund has become one of the key players in identifying and funding frontline research that is changing the face of Alzheimer's research. In 2008, the first phase of its Alzheimer's Genome Project (AGP) with MGH identified several novel Alzheimer's genes and was name a "Top Ten Breakthrough" by TIME magazine.

This study will aim at discovering the genetic switches controlling the Alzheimer genes and how they are triggered by other genes and by environmental inputs. It will examine DNA variants in the Alzheimer genes that influence risk for the disease.